Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events

Abstract

Purpose To capture UK societal health utility values for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and the disutility associated with treatment-related adverse events (AEs) to inform future cost–utility analyses. Methods A literature review, and patient and clinical expert interviews informed the development of health states characterising mHSPC symptoms and the impact of treatment-related AEs on health-related quality of life (HRQL). Three base health states were developed describing a typical patient with high-risk mHSPC: receiving androgen deprivation therapy (ADT) [Base State 1]; receiving docetaxel plus ADT [Base State 2]; completed docetaxel and still receiving ADT whose disease has not yet progressed [Base State 3]. Six additional health states described treatment-related AEs. The health states were validated with experts and piloted with general public participants. Health state utilities were obtained using the time trade-off (TTO) method with 200 members of the UK general population. A generalised estimating equation (GEE) model was used to estimate disutility weights. Results Mean TTO scores for Base State 1 to 3 were 0.71 (SD = 0.26), 0.64 (SD = 0.27), and 0.68 (SD = 0.26), respectively, indicating that receiving docetaxel plus ADT was most impactful on HRQL. The GEE model indicated when compared to Base State 2 that the nausea and vomiting AE had the most impact on HRQL (− 0.21), while alopecia was least burdensome (− 0.04). Conclusions The study highlights the differences in utility between base health states and the significant impact of treatment-related AEs on the HRQL of patients with mHSPC. These findings underline the importance of accounting for impaired HRQL when assessing treatments for mHSPC. Electronic supplementary material The online version of this article (10.1007/s11136-019-02117-9) contains supplementary material, which is available to authorised users.

PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer

“…However, most of these therapies can result in severe side effects and decrease patient quality of life. 2,58 Successful PIM-targeted therapy could be used as a neoadjuvant drug prior to surgery to shrink the tumor and enable more patients to undergo nervesparing radical prostatectomy and therefore improve functional outcomes. 5 Moreover, it has been demonstrated that PIM inhibitors can enhance the efficacy of existing PCa treatments, which will be discussed further, including radiotherapy, 10 chemotherapy, 9 and androgen deprivation.…”

Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States

“…Participants were 100 members of the general public aged over 18 years, recruited by interviewers through informal networks using quota-based convenience sampling, including snowballing, to match the general public in terms of age, sex and ethnicity. The sample size was informed by samples in other published TTO studies [30][31][32][33]. Informed consent was obtained and background sociodemographic questionnaires were completed prior to interview.…”

Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex

“…Patient vignettes were assessed by 100 participants, and caregiver vignettes were assessed separately by 100 participants. The sample sizes are similar to many other published TTO studies [ 19 – 22 ]; no formal sample size calculations were performed as the study did not intend to test a specific hypothesis. In response to the COVID-19 pandemic, all interviews were conducted between August and September 2020 using online video calls (Zoom/Skype).…”